By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapy
Investing

Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapy

News Room
Last updated: 2023/05/15 at 1:25 PM
By News Room
Share
2 Min Read
SHARE

Sarepta Therapeutics Inc.’s stock
SRPT,
+27.99%
soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6 in favor of accelerated approval for the company’s latest gene therapy for Duchenne muscular dystrophy. The vote came late Friday, despite questions about the therapy called SRP-9001’s clinical benefit and safety. . Earlier this week, the FDA said Sarepta did not offer “unambiguous evidence” the therapy will benefit patients with the deadly muscle-wasting disease.  Sarepta, which hopes to gain fast-track approval via the FDA based on limited current data, is conducting a late-stage trial to confirm the therapy’s benefits to patients. The first batch of data from the trial is expected by December; full results should be available in early 2024.The FDA is expected to make a decision by May 29. The agency usually mirrors the  advice of its advisers, though it is not obligated. Oppenheimer analysts, who have an outperform rating on Sarepta stock, said the vote was closer than they expected and noted the discussion was not as positive as they thought among academics, practicing doctors and FDA members. “Overall, the AdCom settled to take a holistic approach in evaluating the data on hand and the discussion leaned forward to give the DMD community a chance. We stay bullish,” they wrote in a note to clients. Sarepta stock has gained 82% in the last 12 months, while the S&P 500
SPX,
+0.31%
has gained 2.5%.

Read the full article here

News Room May 15, 2023 May 15, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Elon Musk wants to launch a new political party. Here’s why some people think it won’t work.

Watch full video on YouTube

Why Even High Earners Are Living Paycheck To Paycheck

Watch full video on YouTube

Bank of America: Higher Yielding Preferred Stock Is Still Attractive (NYSE:BAC)

This article was written byFollowThe Investment Doctor is a financial writer, highlighting…

“Invest in what you know.”

Watch full video on YouTube

‘All the banks were lying’: Tom Hayes on his decade-long battle for justice

The last time Tom Hayes had his picture taken at London’s Southwark…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?